NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis $1.39 -0.14 (-9.15%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.02 (+1.08%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Altimmune Stock (NASDAQ:ALT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Altimmune alerts:Sign Up Key Stats Today's Range$1.38▼$1.5350-Day Range$1.53▼$3.4152-Week Range$1.38▼$6.44Volume4.71 million shsAverage Volume4.12 million shsMarket Capitalization$270.48 millionP/E RatioN/ADividend YieldN/APrice Target$14.33Consensus RatingModerate Buy Company Overview Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine. The company was formed in 2017 through a merger between Altimmune and PharmAthene.AI Generated. May Contain Errors. Read More Altimmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreALT MarketRank™: 3.95127547577 of 5 starsAltimmune scored higher than 79% of companies evaluated by MarketBeat, and ranked 199th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAltimmune has a consensus price target of $14.33, representing about 931.2% upside from its current price of $1.39.Amount of Analyst CoverageAltimmune has only been the subject of 4 research reports in the past 90 days.Read more about Altimmune's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Altimmune are expected to grow in the coming year, from ($0.60) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.01% of the float of Altimmune has been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 12.16, which indicates bearish sentiment.Change versus previous monthShort interest in Altimmune has recently decreased by 0.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.47 News SentimentAltimmune has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Altimmune this week, compared to 5 articles on an average week.Search Interest23 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 53% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Altimmune in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $82,334.00 in company stock, which represents 0.0304% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $82,334.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.60% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALT Stock News HeadlinesAltimmune's (ALT) "Buy" Rating Reiterated at B. Riley FinancialNovember 16 at 2:18 AM | americanbankingnews.comInsider Buying: Altimmune (NASDAQ:ALT) CFO Acquires $16,200.00 in StockNovember 15 at 3:22 PM | insidertrades.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 18 at 1:00 AM | Weiss Ratings (Ad)Altimmune, Inc. (ALT) - What Are Analysts Thinking About This Stock?November 14, 2026 | americanbankingnews.comAltimmune: Still Too Late And Too Capital-IntensiveNovember 12, 2026 | seekingalpha.comAltimmune, Inc. (ALT) Q3 2026 Earnings Call TranscriptNovember 12, 2026 | seekingalpha.comAltimmune, Inc. Q3 2026 Earnings Call SummaryNovember 12, 2026 | finance.yahoo.comAltimmune outlines $480M cash runway through 2029 PERFORMA readout as RESTORE data targeted for 2H 2027November 12, 2026 | seekingalpha.comSee More Headlines ALT Stock Analysis - Frequently Asked Questions How have ALT shares performed this year? Altimmune's stock was trading at $3.61 at the beginning of the year. Since then, ALT shares have decreased by 61.5% and is now trading at $1.39. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02. Read the conference call transcript. When did Altimmune's stock split? Shares of Altimmune reverse split on Friday, September 14th 2018.The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Altimmune's major shareholders? Altimmune's top institutional shareholders include State Street Corp (4.30%), Marshall Wace LLP (2.79%), Goldman Sachs Group Inc. (1.27%) and Nantahala Capital Management LLC (0.88%). Insiders that own company stock include Jerome Benedict Durso, Gregory L Weaver, Wayne Pisano, David Drutz, John Gill and Diane Jorkasky. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Novavax (NVAX), Viking Therapeutics (VKTX), Pfizer (PFE), Vaxart (VXRT) and Tesla (TSLA). Company Calendar Last Earnings11/12/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ALT's financial health is in the Red zone, according to TradeSmith. ALT has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALT CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees57Year Founded1997Price Target and Rating Average Price Target for Altimmune$14.33 High Price Target$20.00 Low Price Target$10.00 Potential Upside/Downside+931.2%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.09 million Net MarginsN/A Pretax Margin-401,361.56% Return on Equity-29.26% Return on Assets-25.48% Debt Debt-to-Equity Ratio0.08 Current Ratio23.93 Quick Ratio23.93 Sales & Book Value Annual Sales$40 thousand Price / Sales6,762.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book0.61Miscellaneous Outstanding Shares194,590,000Free Float191,406,000Market Cap$270.48 million OptionableOptionable Beta0.16 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ALT) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.